CLINICAL USE


Alpha-adrenoceptor blocker:Hypertension Benign prostatic hyperplasia (BPH)

DOSE IN NORMAL RENAL FUNCTION

Hypertension: 1–20 mg once daily BPH: 1–10 mg once daily

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :459.9
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :90–94
  • %Excreted unchanged in urine &nbsp &nbsp : 10
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.5–0.9
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :9–12/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in normal renal function
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Anaesthetics: enhanced hypotensive effect
  • Antidepressants: enhanced hypotensive effect with MAOIs
  • Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect
  • Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect
  • Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect
  • Moxisylyte: possibly severe postural hypotension when used in combination
  • Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect – avoid concomitant use

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Therapy should be initiated with a single dose of 1 mg given at bedtime.